Prognostic Significance of Serum Cysteine-Rich Protein 61 in Patients with Acute Heart Failure

作者：Jingjing Zhao, Chongyu Zhang, Jian Liu, Lili Zhang, Yalin Cao, Dexi Wu, Fengjuan Yao, Ruicong Xue, Huiling Huang, Jingzhou Jiang, Bin Dong, Yu Sun, Yuan Bai, Yugang Dong, Chen Liu · 发表于：Cellular Physiology and Biochemistry · 年份：2018 · DOI：10.1159/000491984 · 被引用次数：20 · 研究领域：Connective Tissue Growth Factor Research、Cardiac Fibrosis and Remodeling、GDF15 and Related Biomarkers

BACKGROUND/AIMS: Cyr61-cysteine-rich protein 61 (CCN1/CYR61) is a multifunctional matricellular protein involved in the regulation of fibrogenesis. Animal experiments have demonstrated that CCN1 can inhibit cardiac fibrosis in cardiac hypertrophy. However, no study has been conducted to assess the relation between serum CCN1 and prognosis of acute heart failure (AHF). METHODS: We measured the serum CCN1 levels of 183 patients with AHF, and the patients were followed up for 6 months. The associations between CCN1 levels and some clinical covariates, especially left ventricular ejection fraction (LVEF), estimated glomerular filtration rate (eGFR), atrial fibrillation and age, were estimated. The AHF patients were followed up for 6 months. The endpoint was all-cause mortality. Kaplan-Meier curve analysis and multivariable Cox proportional hazards analysis were employed to evaluate the prognostic ability of CCN1. We used calibration, discrimination and reclassification to assess the mortality risk prediction of adding CCN1. RESULTS: Serum CCN1 concentrations in AHF patients were significantly increased compared with those in individuals without AHF (237 pg/ml vs. 124.8 pg/ml, p< 0.001). CCN1 level was associated with the level of NT-proBNP (r=0.349, p< 0.001) and was not affected by LVEF, eGFR, age or atrial fibrillation in AHF patients. Importantly, Kaplan-Meier curve analysis illustrated that the AHF patients with serum CCN1 level > 260 pg/ ml had a lower survival rate (p< 0.00...